NCT04687709

Brief Summary

Prostate cancer is the second most common cancer in male cancer globally and ranked third in Hong Kong. While androgen deprivation therapy (ADT) is the backbone treatment for advanced prostate cancer, it could lead to obesity, metabolic syndrome and increased cardiovascular mortality. Previous studies showed that ADT patients have different gut microbiome compared to non-ADT patients and the gut microbiome might be related to the metabolic changes. However, the underlying mechanism of these metabolic complications is still not fully understood. This study aims to investigate the relationship and related mechanism between the changes in gut microbiomes and ADT-related metabolic change in prostate cancer patients.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jan 2021

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 23, 2020

Completed
6 days until next milestone

First Posted

Study publicly available on registry

December 29, 2020

Completed
16 days until next milestone

Study Start

First participant enrolled

January 14, 2021

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 6, 2022

Completed
10 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 26, 2023

Completed
Last Updated

January 5, 2024

Status Verified

January 1, 2024

Enrollment Period

1.9 years

First QC Date

December 23, 2020

Last Update Submit

January 3, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • To assess the changes in gut microbiota in prostate cancer patients after initiation of androgen deprivation therapy (ADT)

    Gut microbiome related metabolites will be measured by ELISA and mass spectrometry.

    Baseline, Month 3, Month 6

Eligibility Criteria

Age45 Years+
Sexmale
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients diagnosed with prostate cancer and is going to receive ADT treatment will be recruited.

You may qualify if:

  • Male subject with age 45 or above
  • Histological diagnosis of prostate cancer (acinar type)
  • Clinically decided for androgen deprivation therapy (ADT) as treatment for prostate cancer

You may not qualify if:

  • History of diabetes
  • Patients that have other active treatment for prostate cancer or other cancers (except ADT)
  • Patients received treatment, either surgical or medical, that could lead to decrease in serum testosterone prior to commencement of ADT
  • Patients will be started on other treatments, including chemotherapy, new generation of androgen-receptor targeted agents, radiotherapy etc, within 6 months of the commencement of ADT.
  • Subject with recent antibiotics usage within 3 months.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Prince of Wales Hospital

Shatin, Hong Kong

Location

Related Publications (27)

  • Chan SY, Ng CF, Lee KW, Yee CH, Chiu PK, Teoh JY, Hou SS. Differences in cancer characteristics of Chinese patients with prostate cancer who present with different symptoms. Hong Kong Med J. 2017 Feb;23(1):6-12. doi: 10.12809/hkmj164875. Epub 2016 Dec 9.

    PMID: 27932742BACKGROUND
  • Dao MC, Clement K. Gut microbiota and obesity: Concepts relevant to clinical care. Eur J Intern Med. 2018 Feb;48:18-24. doi: 10.1016/j.ejim.2017.10.005. Epub 2017 Oct 27.

    PMID: 29110901BACKGROUND
  • Wong MC, Goggins WB, Wang HH, Fung FD, Leung C, Wong SY, Ng CF, Sung JJ. Global Incidence and Mortality for Prostate Cancer: Analysis of Temporal Patterns and Trends in 36 Countries. Eur Urol. 2016 Nov;70(5):862-874. doi: 10.1016/j.eururo.2016.05.043. Epub 2016 Jun 8.

    PMID: 27289567BACKGROUND
  • Saylor PJ, Smith MR. Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer. J Natl Compr Canc Netw. 2010 Feb;8(2):211-23. doi: 10.6004/jnccn.2010.0014.

    PMID: 20141678BACKGROUND
  • Teoh JY, Chan SY, Chiu PK, Poon DM, Cheung HY, Hou SS, Ng CF. Risk of acute myocardial infarction after androgen-deprivation therapy for prostate cancer in a Chinese population. BJU Int. 2015 Sep;116(3):382-7. doi: 10.1111/bju.12967. Epub 2015 Mar 7.

    PMID: 25327618BACKGROUND
  • Teoh JY, Chiu PK, Chan SY, Poon DM, Cheung HY, Hou SS, Ng CF. Risk of ischemic stroke after androgen deprivation therapy for prostate cancer in the Chinese population living in Hong Kong. Jpn J Clin Oncol. 2015 May;45(5):483-7. doi: 10.1093/jjco/hyv025. Epub 2015 Feb 26.

    PMID: 25724216BACKGROUND
  • Teoh JY, Chiu PK, Chan SY, Poon DM, Cheung HY, Hou SS, Ng CF. Risk of new-onset diabetes after androgen deprivation therapy for prostate cancer in the Asian population. J Diabetes. 2015 Sep;7(5):672-80. doi: 10.1111/1753-0407.12226. Epub 2014 Dec 22.

    PMID: 25266491BACKGROUND
  • Wong SH, Kwong TNY, Wu CY, Yu J. Clinical applications of gut microbiota in cancer biology. Semin Cancer Biol. 2019 Apr;55:28-36. doi: 10.1016/j.semcancer.2018.05.003. Epub 2018 May 18.

    PMID: 29782923BACKGROUND
  • Li JKM, Chiu PKF, Ng CF. The impact of microbiome in urological diseases: a systematic review. Int Urol Nephrol. 2019 Oct;51(10):1677-1697. doi: 10.1007/s11255-019-02225-y. Epub 2019 Jul 12.

    PMID: 31301004BACKGROUND
  • Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature. 2006 Dec 21;444(7122):1022-3. doi: 10.1038/4441022a.

    PMID: 17183309BACKGROUND
  • Dabke K, Hendrick G, Devkota S. The gut microbiome and metabolic syndrome. J Clin Invest. 2019 Oct 1;129(10):4050-4057. doi: 10.1172/JCI129194.

    PMID: 31573550BACKGROUND
  • Boutagy NE, McMillan RP, Frisard MI, Hulver MW. Metabolic endotoxemia with obesity: Is it real and is it relevant? Biochimie. 2016 May;124:11-20. doi: 10.1016/j.biochi.2015.06.020. Epub 2015 Jun 29.

    PMID: 26133659BACKGROUND
  • den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud DJ, Bakker BM. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J Lipid Res. 2013 Sep;54(9):2325-40. doi: 10.1194/jlr.R036012. Epub 2013 Jul 2.

    PMID: 23821742BACKGROUND
  • Neuman H, Debelius JW, Knight R, Koren O. Microbial endocrinology: the interplay between the microbiota and the endocrine system. FEMS Microbiol Rev. 2015 Jul;39(4):509-21. doi: 10.1093/femsre/fuu010. Epub 2015 Feb 19.

    PMID: 25701044BACKGROUND
  • Santos-Marcos JA, Rangel-Zuniga OA, Jimenez-Lucena R, Quintana-Navarro GM, Garcia-Carpintero S, Malagon MM, Landa BB, Tena-Sempere M, Perez-Martinez P, Lopez-Miranda J, Perez-Jimenez F, Camargo A. Influence of gender and menopausal status on gut microbiota. Maturitas. 2018 Oct;116:43-53. doi: 10.1016/j.maturitas.2018.07.008. Epub 2018 Jul 19.

    PMID: 30244778BACKGROUND
  • Zhao H, Chen J, Li X, Sun Q, Qin P, Wang Q. Compositional and functional features of the female premenopausal and postmenopausal gut microbiota. FEBS Lett. 2019 Sep;593(18):2655-2664. doi: 10.1002/1873-3468.13527. Epub 2019 Jul 17.

    PMID: 31273779BACKGROUND
  • Harada N, Hanaoka R, Horiuchi H, Kitakaze T, Mitani T, Inui H, Yamaji R. Castration influences intestinal microflora and induces abdominal obesity in high-fat diet-fed mice. Sci Rep. 2016 Mar 10;6:23001. doi: 10.1038/srep23001.

    PMID: 26961573BACKGROUND
  • Gao W, Wu D, Wang Y, Wang Z, Zou C, Dai Y, Ng CF, Teoh JY, Chan FL. Development of a novel and economical agar-based non-adherent three-dimensional culture method for enrichment of cancer stem-like cells. Stem Cell Res Ther. 2018 Sep 26;9(1):243. doi: 10.1186/s13287-018-0987-x.

    PMID: 30257704BACKGROUND
  • Tsoi TH, Chan CF, Chan WL, Chiu KF, Wong WT, Ng CF, Wong KL. Urinary Polyamines: A Pilot Study on Their Roles as Prostate Cancer Detection Biomarkers. PLoS One. 2016 Sep 6;11(9):e0162217. doi: 10.1371/journal.pone.0162217. eCollection 2016.

    PMID: 27598335BACKGROUND
  • Teoh JY, Ng CF. Cardiovascular risk after androgen deprivation therapy for prostate cancer: an Asian perspective. Int Urol Nephrol. 2016 Sep;48(9):1429-35. doi: 10.1007/s11255-016-1337-5. Epub 2016 Jun 2.

    PMID: 27256399BACKGROUND
  • Cheung MK, Lam WY, Fung WY, Law PT, Au CH, Nong W, Kam KM, Kwan HS, Tsui SK. Sputum microbiota in tuberculosis as revealed by 16S rRNA pyrosequencing. PLoS One. 2013;8(1):e54574. doi: 10.1371/journal.pone.0054574. Epub 2013 Jan 24.

    PMID: 23365674BACKGROUND
  • Hui AW, Lau HW, Chan TH, Tsui SK. The human microbiota: a new direction in the investigation of thoracic diseases. J Thorac Dis. 2013 Aug;5 Suppl 2(Suppl 2):S127-31. doi: 10.3978/j.issn.2072-1439.2013.07.41.

    PMID: 23977433BACKGROUND
  • Liu Y, Wong KK, Ko EY, Chen X, Huang J, Tsui SK, Li TC, Chim SS. Systematic Comparison of Bacterial Colonization of Endometrial Tissue and Fluid Samples in Recurrent Miscarriage Patients: Implications for Future Endometrial Microbiome Studies. Clin Chem. 2018 Dec;64(12):1743-1752. doi: 10.1373/clinchem.2018.289306. Epub 2018 Sep 20.

    PMID: 30237148BACKGROUND
  • Chan CWH, Leung TF, Choi KC, Tsui SKW, Chan JYW. Effects of gut microbiome and environment on the development of eczema in Chinese infants. Medicine (Baltimore). 2020 May 22;99(21):e20327. doi: 10.1097/MD.0000000000020327.

    PMID: 32481318BACKGROUND
  • Wong SH, Yu J. Gut microbiota in colorectal cancer: mechanisms of action and clinical applications. Nat Rev Gastroenterol Hepatol. 2019 Nov;16(11):690-704. doi: 10.1038/s41575-019-0209-8. Epub 2019 Sep 25.

    PMID: 31554963BACKGROUND
  • Yu J, Feng Q, Wong SH, Zhang D, Liang QY, Qin Y, Tang L, Zhao H, Stenvang J, Li Y, Wang X, Xu X, Chen N, Wu WK, Al-Aama J, Nielsen HJ, Kiilerich P, Jensen BA, Yau TO, Lan Z, Jia H, Li J, Xiao L, Lam TY, Ng SC, Cheng AS, Wong VW, Chan FK, Xu X, Yang H, Madsen L, Datz C, Tilg H, Wang J, Brunner N, Kristiansen K, Arumugam M, Sung JJ, Wang J. Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. Gut. 2017 Jan;66(1):70-78. doi: 10.1136/gutjnl-2015-309800. Epub 2015 Sep 25.

    PMID: 26408641BACKGROUND
  • Ng CF, Chiu PKF, Yee CH, Lau BSY, Leung SCH, Teoh JYC. Effect of androgen deprivation therapy on cardiovascular function in Chinese patients with advanced prostate cancer: a prospective cohort study. Sci Rep. 2020 Oct 22;10(1):18060. doi: 10.1038/s41598-020-75139-w.

    PMID: 33093594BACKGROUND

Related Links

Biospecimen

Retention: SAMPLES WITH DNA

Total bacterial DNA will be extracted from fecal samples by using the bead-beating method with Qiagen QIAamp PowerFecal Pro DNA kit. The extracted DNA will be quantified by Nanodrop for polymerase chain reaction (PCR)

MeSH Terms

Conditions

Prostatic Neoplasms

Condition Hierarchy (Ancestors)

Genital Neoplasms, MaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsGenital Diseases, MaleGenital DiseasesUrogenital DiseasesProstatic DiseasesMale Urogenital Diseases

Study Officials

  • Chi Fai NG, MD

    Chinese University of Hong Kong

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

December 23, 2020

First Posted

December 29, 2020

Study Start

January 14, 2021

Primary Completion

December 6, 2022

Study Completion

September 26, 2023

Last Updated

January 5, 2024

Record last verified: 2024-01

Data Sharing

IPD Sharing
Will not share

Locations